Limits...
Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review.

Kaufman KR, Velez AE, Wong S, Mani R - Epilepsy Behav Case Rep (2012)

Bottom Line: Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization.Cardiac monitoring may be required for at-risk patients on LCM.Clinicians need to be cognizant of this potential adverse effect.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, 125 Paterson Street, Suite #2200, New Brunswick, NJ 08901, USA ; Department of Neurology, UMDNJ-Robert Wood Johnson Medical School, 125 Paterson Street, Suite #6200, New Brunswick, NJ 08901, USA ; Department of Anesthesiology, UMDNJ-Robert Wood Johnson Medical School, 125 Paterson Street, Suite #3100, New Brunswick, NJ 08901, USA.

ABSTRACT
Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization. Lacosamide dose-dependent dysrhythmias (PR-interval prolongation, AV block, and atrial fibrillation/flutter) have been reported. This case represents the first instance of LCM-induced atrial fibrillation following a low loading dose (200 mg). Risk factors for atrial fibrillation are addressed and discussed in the context of this case. Full cardiac history is recommended prior to patients being initiated on LCM. Cardiac monitoring may be required for at-risk patients on LCM. Clinicians need to be cognizant of this potential adverse effect.

No MeSH data available.


Related in: MedlinePlus

Initial routine EEG.
© Copyright Policy - CC BY-NC-SA
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4150593&req=5

f0005: Initial routine EEG.

Mentions: Initial routine EEG revealed 1) disorganized background characterized by diffuse slowing with frontally predominant theta and delta activities and intermittent semi-rhythmic delta activity; 2) intermittent left fronto-temporal polymorphic delta activity; and 3) few left fronto-temporal high-amplitude sharp waves (Fig. 1). Clinical presentation and EEG were consistent with partial epilepsy with left temporal region complex partial seizures.


Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review.

Kaufman KR, Velez AE, Wong S, Mani R - Epilepsy Behav Case Rep (2012)

Initial routine EEG.
© Copyright Policy - CC BY-NC-SA
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4150593&req=5

f0005: Initial routine EEG.
Mentions: Initial routine EEG revealed 1) disorganized background characterized by diffuse slowing with frontally predominant theta and delta activities and intermittent semi-rhythmic delta activity; 2) intermittent left fronto-temporal polymorphic delta activity; and 3) few left fronto-temporal high-amplitude sharp waves (Fig. 1). Clinical presentation and EEG were consistent with partial epilepsy with left temporal region complex partial seizures.

Bottom Line: Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization.Cardiac monitoring may be required for at-risk patients on LCM.Clinicians need to be cognizant of this potential adverse effect.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, 125 Paterson Street, Suite #2200, New Brunswick, NJ 08901, USA ; Department of Neurology, UMDNJ-Robert Wood Johnson Medical School, 125 Paterson Street, Suite #6200, New Brunswick, NJ 08901, USA ; Department of Anesthesiology, UMDNJ-Robert Wood Johnson Medical School, 125 Paterson Street, Suite #3100, New Brunswick, NJ 08901, USA.

ABSTRACT
Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization. Lacosamide dose-dependent dysrhythmias (PR-interval prolongation, AV block, and atrial fibrillation/flutter) have been reported. This case represents the first instance of LCM-induced atrial fibrillation following a low loading dose (200 mg). Risk factors for atrial fibrillation are addressed and discussed in the context of this case. Full cardiac history is recommended prior to patients being initiated on LCM. Cardiac monitoring may be required for at-risk patients on LCM. Clinicians need to be cognizant of this potential adverse effect.

No MeSH data available.


Related in: MedlinePlus